New Brunswick, NJ - According to Anjalee Khemlani, "A New Jersey institute will be one of two sites nationwide for a bladder cancer vaccine clinical trial. Rutgers Cancer Institute of New Jersey in New Brunswick will study the effect of this new vaccine, PANVAC, alongside current treatments."
Currently, high grade non-muscle invasive bladder cancer is treated with bacillus Calmette-Guerin, or BCG. BCG is a liquid delivered into the bladder through a catheter, which is then removed, leaving the medicine inside the bladder. This method has proven to be effective in slowing the cancer growth or prevent it from coming back if delivered after a surgery.
The new trial is sponsored by the National Cancer Institute.
Eric Singer, urologic oncologist at the Cancer Institute and assistant professor of surgery at Rutgers Robert Wood Johnson Medical School, is the lead researcher on the study.
“Other than a radical cystectomy — surgical removal of the bladder — there are limited options for patients with this type of bladder cancer. By exploring the combined use of existing therapies in a novel way, there is an opportunity to address an unmet need in this patient population,” he said.
The new trial is sponsored by the National Cancer Institute.
Eric Singer, urologic oncologist at the Cancer Institute and assistant professor of surgery at Rutgers Robert Wood Johnson Medical School, is the lead researcher on the study.
“Other than a radical cystectomy — surgical removal of the bladder — there are limited options for patients with this type of bladder cancer. By exploring the combined use of existing therapies in a novel way, there is an opportunity to address an unmet need in this patient population,” he said.
